Compare Ingersoll Rand (IR) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ingersoll Rand vs Organon & Co. Common Stock — how do they compare? Ingersoll Rand trades at $77.95 (market cap $30.63B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Ingersoll Rand is far larger — about 8.5× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays the higher dividend (0.58%). Which is the better fit depends on your goals — on Pluang, investors hold Ingersoll Rand for 9 Days and Organon & Co. Common Stock for 0 Days on average.
| IR | OGN | |
|---|---|---|
Market Cap | $30.63B | $3.62B |
Volume | 3,342,496 | 2,892,999 |
Sector | Industrials | Health |
52-Week High | $98.76 | $13.81 |
52-Week Low | $68.54 | $5.70 |
Typical Hold Time | 9 Days | 0 Days |
Enterprise Value | $34.29B | $11.04B |
Dividend Yield | 0.1% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ingersoll Rand (IR) trades at $78.95, down 0.18% with a bullish technical signal. The company shows strong fundamentals with Q2 2026 EPS beating estimates at $0.86 versus $0.827 expected, marking three consecutive quarterly beats. Revenue guidance was raised to 4.5%-6.5% for 2026, with improving demand across business cycles. Analyst consensus is bullish with a $90.60 price target, representing 15% upside potential from current levels.
The outlook remains positive with accelerating long-cycle orders and strategic acquisitions expanding capabilities. Key risks include margin compression and elevated P/E ratio of 32.62. Institutional ownership increased with HSBC boosting its position by 12.9% in Q2 2026. The stock offers growth potential but requires monitoring of profitability trends and valuation sustainability.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Ingersoll Rand
Ingersoll Rand develops industrial technologies for creating and managing flow, pressure, and motion. Its portfolio includes compressors, pumps, vacuum systems, and other equipment used across industrial markets.
Read more on IR →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
